Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2282492 | 0.83 | HPGD (0.65) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL14075485 | 0.81 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL13841454 | 0.81 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL10238819 | 0.80 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL16569387 | 0.80 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL6607271 | 0.80 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL21177278 | 0.80 | MAPT (0.59) | ALDH1A1MAPTKDM4E | |
| SCHEMBL4594156 | 0.80 | SMN1; SMN2 (0.74) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL11273760 | 0.78 | KDM4E (0.65) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 | |
| SCHEMBL31558412 | 0.77 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HPGDMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2012-01-19 | — | — | US | disclosed |
| US-8053440-B2 | Compounds for the prevention and treatment of cardiovascular diseases | Resverlogix Corporation (CA) | 2011-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015905-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885SMN1; SMN2 3476/4885HPGD 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.